Compounds > succinobucol
Page last updated: 2024-09-05

succinobucol and cardiovascular agents

succinobucol has been researched along with cardiovascular agents in 3 studies

Compound Research Comparison

Studies
(succinobucol)		Trials
(succinobucol)		Recent Studies (post-2010)
(succinobucol)		Studies
(cardiovascular agents)		Trials
(cardiovascular agents)		Recent Studies (post-2010) (cardiovascular agents)
5351617,6451,4806,891

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agbani, EO; Behnisch, B; Czudaj, P; Kennedy, S; McCormick, C; McPhaden, A; Mullen, A; Oldroyd, KG; Wadsworth, RM; Watt, J1
Biswal, S1
Chen, Y; Liu, Z; Shi, S; Wang, X; Zhang, Y; Zheng, Z; Zhu, H1

Other Studies

3 other study(ies) available for succinobucol and cardiovascular agents

ArticleYear
Succinobucol-eluting stents increase neointimal thickening and peri-strut inflammation in a porcine coronary model.
    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Volume: 81, Issue:4

    Topics: Animals; Cardiovascular Agents; Cattle; Cell Survival; Cells, Cultured; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Eluting Stents; Endothelial Cells; Fibrin; Inflammation; Male; Metals; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Neointima; Percutaneous Coronary Intervention; Probucol; Prosthesis Design; Sirolimus; Swine

2013
Novel cardiovascular drugs in clinical trials.
    Indian journal of medical sciences, 2010, Volume: 64, Issue:6

    Topics: Anticholesteremic Agents; Benzaldehydes; Cardiovascular Agents; Cardiovascular Diseases; Clinical Trials as Topic; Endothelin Receptor Antagonists; Fibrinolytic Agents; Humans; Immunologic Factors; Isoxazoles; Lipoxygenase Inhibitors; Metalloendopeptidases; Oxazolidinones; Oximes; Phospholipase A2 Inhibitors; Probucol; Pyrimidines; Quinolines; Thiophenes

2010
Novel ASK1 Inhibitor AGI-1067 Attenuates AGE-Induced Fibrotic Response by Suppressing the MKKs/p38 MAPK Pathway in Human Coronary Arterial Smooth Muscle Cells.
    International heart journal, 2018, Nov-28, Volume: 59, Issue:6

    Topics: Blotting, Western; Cardiovascular Agents; Cells, Cultured; Coronary Vessels; Fibrosis; Glycation End Products, Advanced; Humans; Immunoprecipitation; MAP Kinase Kinase 3; MAP Kinase Kinase 6; MAP Kinase Kinase Kinase 5; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; p38 Mitogen-Activated Protein Kinases; Probucol; Signal Transduction

2018